开云app官网登录入口网页版-官方正版

#罗氏安维汀#

4篇内容 | 836人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1701453, encodeId=a49a1e01453ff, content=<a href='/topic/show?id=c72ee9614da' target=_blank style='color:#2F92EE;'>#罗氏安维汀#</a>, objectTitle=罗氏安维汀（贝伐珠单抗注射液）胶质母细胞瘤适应症获批，为中国患者带来全新治疗选择, objectType=article, longId=201078, objectId=94a22010e8b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94a22010e8b1, replyNumber=0, likeNumber=58, createdTime=2020-09-27, rootId=0, userName=手留余香, userId=92cd30370684, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94a22010e8b1, moduleTitle=罗氏安维汀（贝伐珠单抗注射液）胶质母细胞瘤适应症获批，为中国患者带来全新治疗选择, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=94a22010e8b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1701451, encodeId=c36c1e014514c, content=<a href='/topic/show?id=c72ee9614da' target=_blank style='color:#2F92EE;'>#罗氏安维汀#</a>, objectTitle=FDA批准罗氏安维汀（Avastin）联合化疗治疗晚期宫颈癌, objectType=article, longId=39215, objectId=fcdb3921526, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcdb3921526, replyNumber=0, likeNumber=63, createdTime=2015-06-12, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcdb3921526, moduleTitle=FDA批准罗氏安维汀（Avastin）联合化疗治疗晚期宫颈癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fcdb3921526)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1701450, encodeId=b3461e01450fa, content=<a href='/topic/show?id=c72ee9614da' target=_blank style='color:#2F92EE;'>#罗氏安维汀#</a>, objectTitle=欧盟批准罗氏安维汀（Avastin）用于铂耐药复发性卵巢癌, objectType=article, longId=38832, objectId=1f85388327a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f85388327a, replyNumber=0, likeNumber=61, createdTime=2015-07-13, rootId=0, userName=手留余香, userId=92cd30370684, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f85388327a, moduleTitle=欧盟批准罗氏安维汀（Avastin）用于铂耐药复发性卵巢癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1f85388327a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1701452, encodeId=cdaa1e014527b, content=<a href='/topic/show?id=c72ee9614da' target=_blank style='color:#2F92EE;'>#罗氏安维汀#</a>, objectTitle=里程碑！欧盟批准罗氏安维汀（Avastin）联合化疗治疗晚期宫颈癌, objectType=article, longId=49147, objectId=a38a4914ee9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a38a4914ee9, replyNumber=0, likeNumber=81, createdTime=2015-08-28, rootId=0, userName=手留余香, userId=92cd30370684, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a38a4914ee9, moduleTitle=里程碑！欧盟批准罗氏安维汀（Avastin）联合化疗治疗晚期宫颈癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a38a4914ee9)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

罗氏安维汀

2020-05-29

手留余香 (审核中...)

前往app查看评论内容

#罗氏安维汀#

罗氏安维汀（贝伐珠单抗注射液）胶质母细胞瘤适应症获批，为中国患者带来全新治疗选择

2020-09-27

医者仁心 (审核中...)

前往app查看评论内容

#罗氏安维汀#

FDA批准罗氏安维汀（Avastin）联合化疗治疗晚期宫颈癌

2015-06-12

手留余香 (审核中...)

前往app查看评论内容

#罗氏安维汀#

欧盟批准罗氏安维汀（Avastin）用于铂耐药复发性卵巢癌

2015-07-13

手留余香 (审核中...)

前往app查看评论内容

#罗氏安维汀#

里程碑！欧盟批准罗氏安维汀（Avastin）联合化疗治疗晚期宫颈癌

2015-08-28

科室
- - 订阅+
  - 更多科室
工具
服务